GlaxoSmithKline has divulged mas-related G protein-coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of osteoarthritis, migraine, asthma, irritable bowel syndrome, atopic dermatitis, psoriasis, urticaria and rheumatoid arthritis, among other disorders.

In a recent study, researchers from Shanghai Jiao Tong University in China investigated the epigenetic program responsible for cartilage injury induced by aberrant mechanical force, with the final aim of exploring a potential epigenetic-based therapy approach for osteoarthritis.

Post-traumatic OA (PTOA) is a specific type of osteoarthritis (OA) caused by injury. Both OA and PTOA are caused by an imbalance in catabolic and anabolic processes in articular cartilage as well as proinflammatory changes throughout the joint, which lead to joint degeneration and pain.